599 related articles for article (PubMed ID: 31332467)
1. Turkish validation of the overactive bladder symptom score (OABSS) and evaluation of mirabegron treatment response.
Culha MG; Degirmentepe RB; Ozbir S; Cakir SS; Homma Y
Int Urogynecol J; 2019 Dec; 30(12):2121-2126. PubMed ID: 31332467
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
[TBL] [Abstract][Full Text] [Related]
3. The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment.
Chou EC; Hung MJ; Yen TW; Chuang YC; Meng E; Huang ST; Kuo HC
J Formos Med Assoc; 2014 Aug; 113(8):506-12. PubMed ID: 25037757
[TBL] [Abstract][Full Text] [Related]
4. A multicenter prospective study for overactive bladder patient treatment satisfaction with mirabegron after being unsatisfied with antimuscarinic therapy (FAVOR study).
Ko KJ; Choo MS; Chang YS; Kim JC; Lee KS
Neurourol Urodyn; 2020 Nov; 39(8):2417-2424. PubMed ID: 32894793
[TBL] [Abstract][Full Text] [Related]
5. Reliability of the Polish version of the Overactive Bladder Symptom Score (OABSS) questionnaire : Correlation of the OABSS with urodynamic study and the UDI-6 and IIQ-7 questionnaires.
Wróbel A; Skorupska K; Rechberger E; Woźniak A; Miotla P; Kubik-Komar A; Skorupski P; Rechberger T
Int Urogynecol J; 2019 Dec; 30(12):2135-2139. PubMed ID: 31396639
[TBL] [Abstract][Full Text] [Related]
6. Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study).
Nakagomi H; Mitsui T; Shimura H; Ihara T; Kira S; Sawada N; Takeda M
BMC Urol; 2022 Mar; 22(1):40. PubMed ID: 35313873
[TBL] [Abstract][Full Text] [Related]
7. Mirabegron for treatment of overactive bladder symptoms in patients with Parkinson's disease: A double-blind, randomized placebo-controlled trial (Parkinson's Disease Overactive bladder Mirabegron, PaDoMi Study).
Cho SY; Jeong SJ; Lee S; Kim J; Lee SH; Choo MS; Oh SJ
Neurourol Urodyn; 2021 Jan; 40(1):286-294. PubMed ID: 33389776
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy of low-dose (25 mg) mirabegron therapy for patients with mild to moderate overactive bladder symptoms due to central nervous system diseases.
Chen SF; Kuo HC
Low Urin Tract Symptoms; 2019 Apr; 11(2):O53-O58. PubMed ID: 29380517
[TBL] [Abstract][Full Text] [Related]
9. Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE).
Carlson KV; Rovner ES; Nair KV; Deal AS; Kristy RM; Schermer CR
Adv Ther; 2019 Aug; 36(8):1906-1921. PubMed ID: 31222714
[TBL] [Abstract][Full Text] [Related]
10. Higher urge severity score predicts resumption of overactive bladder (OAB) medication following discontinuation of mirabegron treatment in patients with OAB.
Wang CC; Jiang YH; Kuo HC
Low Urin Tract Symptoms; 2019 Apr; 11(2):O180-O185. PubMed ID: 30565417
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of mirabegron for overactive bladder with human T cell lymphotropic virus-1 associated myelopathy.
Matsuo T; Miyata Y; Nakamura T; Satoh K; Sakai H
Low Urin Tract Symptoms; 2019 Apr; 11(2):O65-O70. PubMed ID: 29473309
[TBL] [Abstract][Full Text] [Related]
12. A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study).
Yamanishi T; Kaga K; Sakata K; Yokoyama T; Kageyama S; Fuse M; Tokunaga S
Neurourol Urodyn; 2020 Feb; 39(2):804-812. PubMed ID: 31961963
[TBL] [Abstract][Full Text] [Related]
13. Three-year safety, efficacy and persistence data following the daily use of mirabegron for overactive bladder in the clinical setting: A Japanese post-marketing surveillance study.
Kato D; Tabuchi H; Uno S
Low Urin Tract Symptoms; 2019 Apr; 11(2):O152-O161. PubMed ID: 30079630
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of transcutaneous electrical nerve stimulation combined with mirabegron therapy compared with mirabegron monotherapy for overactive bladder: a prospective randomized controlled study.
Zhao L; Wu F; Wang J; Wang Y; Peng W; Chen Y
World J Urol; 2024 Jun; 42(1):370. PubMed ID: 38847900
[TBL] [Abstract][Full Text] [Related]
15. Mirabegron as a treatment for overactive bladder symptoms in men (MIRACLE study): Efficacy and safety results from a multicenter, randomized, double-blind, placebo-controlled, parallel comparison phase IV study.
Shin DG; Kim HW; Yoon SJ; Song SH; Kim YH; Lee YG; Joo KJ; Bae JH; Kang TW; Jeong SJ; Woo SH; Yoo ES; Son H; Koo KC; Kim SW
Neurourol Urodyn; 2019 Jan; 38(1):295-304. PubMed ID: 30311691
[TBL] [Abstract][Full Text] [Related]
16. Intravesical prostatic protrusion does not compromise the therapeutic effects of Mirabegron in male patients with overactive bladder.
Shen YC; Wang HJ; Lee WC; Chen CH; Chuang YC
Int J Clin Pract; 2020 Sep; 74(9):e13537. PubMed ID: 32438481
[TBL] [Abstract][Full Text] [Related]
17. Reliability of Thai-Version Overactive Bladder Symptom Scores (OABSS) Questionnaire and the Correlations of OABSS with Voiding Diary, International Prostate Symptom Score (IPSS), and Patient Perception of Bladder Condition (PPBC) Questionnaires.
Bunyavejchevin S
J Med Assoc Thai; 2015 Nov; 98(11):1064-74. PubMed ID: 26817176
[TBL] [Abstract][Full Text] [Related]
18. Impact of combined usage of questionnaire forms with bladder diary for overactive bladder syndrome.
Sonbahar AE; Durmaz K; Culha MG
Urologia; 2022 Nov; 89(4):517-520. PubMed ID: 35471101
[TBL] [Abstract][Full Text] [Related]
19. Comparison in the efficacy of fesoterodine or mirabegron add-on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: A randomized, prospective trial using urodynamic studies.
Matsukawa Y; Takai S; Majima T; Funahashi Y; Sassa N; Kato M; Yamamoto T; Gotoh M
Neurourol Urodyn; 2019 Mar; 38(3):941-949. PubMed ID: 30779375
[TBL] [Abstract][Full Text] [Related]
20. How durable is the effect of mirabegron in successfully-treated overactive bladder patients? Analysis of a multicentre study.
Švabík K; Mašata J; Krhut J; Zachoval R; Hanuš T; Halaška M; Martan A
Ceska Gynekol; 2018; 83(3):164-168. PubMed ID: 30764614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
